OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

September 30, 2011

Study Completion Date

July 31, 2013

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

erlotinib

Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.

Trial Locations (1)

43210

Ohio State University, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER